Trevi Therapeutics, Inc. (TRVI)

Trevi Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	32.4	12.59	36.83	45	57.31
Short-Term Investments	50.57	107.92	0	0	0
Cash & Cash Equivalents	82.97	120.51	36.83	45	57.31
Cash Growth	-31.15%	227.21%	-18.16%	-21.48%	695.79%
Other Current Assets	4.58	2.11	1.13	1.27	2.24
Total Current Assets	87.55	122.62	37.96	46.27	59.55
Property, Plant & Equipment	1.56	0.19	0.18	0.33	0.43
Other Long-Term Assets	0.3	0.21	0.33	0.53	0.02
Total Long-Term Assets	1.86	0.4	0.52	0.86	0.45
Total Assets	89.4	123.02	38.48	47.13	60
Accounts Payable	1.81	2.86	2.85	2.02	1.6
Current Debt	0.31	7.03	6.07	0.11	0.1
Other Current Liabilities	3.71	3.52	3.81	3.43	3.5
Total Current Liabilities	5.82	13.4	12.72	5.56	5.2
Long-Term Debt	1.03	2.15	8.68	14.29	0.26
Other Long-Term Liabilities	0	0	0	0	0
Total Long-Term Liabilities	1.03	2.16	8.68	14.29	0.26
Total Liabilities	6.86	15.56	21.4	19.85	5.46
Total Debt	1.34	9.18	14.74	14.41	0.36
Debt Growth	-85.42%	-37.75%	2.33%	3946.91%	673.91%
Retained Earnings	-239.13	-210.07	-180.92	-146.98	-114.22
Comprehensive Income	-0.03	-0.12	0	0	0
Shareholders' Equity	82.55	107.46	17.08	27.28	54.55
Net Cash / Debt	81.63	111.33	22.09	30.59	56.96
Net Cash / Debt Growth	-26.68%	404.06%	-27.81%	-46.29%	695.93%
Net Cash Per Share	0.82	1.72	0.97	1.69	4.85
Working Capital	81.72	109.22	25.23	40.71	54.35
Book Value Per Share	0.83	1.67	0.75	1.51	4.65

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).